FDA accepts Genentech vamikibart BLA for uveitic macular edema
The FDA accepted Genentech’s biologics license application for vamikibart to treat uveitic macular edema, with an approval decision expected by July 2027. Submissions were also filed and accepted in the EU, China and Japan.
1. Regulatory submissions
The FDA accepted Genentech’s biologics license application for vamikibart to treat uveitic macular edema. An approval decision is expected by July 2027. Regulatory submissions were also filed and accepted in the EU, China and Japan.
